The TCG cluster is involved in developing precision oncology approaches to individualize patient therapies, using imaging, genomics, proteogenomics and bioinformatics approaches.
The aim is to characterize drivers of treatment resistance and metastatic disease, to ultimately profile and predict high risk groups, identify combination targeting strategies, inform treatment, and contribute to individual and population prevention strategies, through testing of hypotheses related to cancer dynamics and evolution. These analyses will fuel clinically testable hypotheses and thus drive the creation of new results and treatment paradigms in cancer to reduce the burden of treatment resistance, and through national and international collaborations, translate these across BC, Canada and beyond.
The TCG leaders are pleased to be able to offer a funding program to support trainees in collaborative efforts in translational cancer genomics. Program details
Researchers in the Cluster
David Scott